The tiny microbes located inside the intestines could play a critical role in heart attack recovery, according to a new study that found gut bacteria helpful in repairing the damage after a heart attack. But […]
ENTEROME SA, a clinical-stage biotech company developing innovative therapies to treat microbiome-associated diseases with a focus on auto-immune disease and cancer, has entered into a global licensing, co-development and co-promotion agreement with Takeda Pharmaceutical Company […]
With a growing body of science linking gut microbiota to inflammatory bowel disease (IBD), a need exists in clinical settings to understand changes in the gut microbial community as they relate to IBD and its […]
Symberix, a preclinical stage company dedicated to the development of novel pharmaceutical treatments for lower gastrointestinal (GI) disorders, has been awarded three Small Business Innovation Research (SBIR) grants from the National Institutes of Health (NIH), […]
Patients with cystic fibrosis (CF), a genetic disease that causes a persistent buildup of thick mucus in their lungs and other organs, suffer from chronic bacterial infections and inflammation that often lead to deadly respiratory […]
LNC Therapeutics, a French biotech company specializing in gut microbiome-based drug discovery announced that it has signed an exclusive license agreement with Cornell University (Ithaca, NY, USA ) for its Christensenella patent family. Christensenella is a recently […]
Eagle Genomics announce partnership with Microsoft Genomics, a Microsoft Azure service dedicated to meeting the computational challenges of the genomics era. This is the first Microsoft partner focused in the microbiome genomics market. Microbiomics is […]
MaaT Pharma has announced the dosing of the first patient in a Phase 2 clinical trial of its lead microbiome restoration candidate, MaaT013, in patients with steroid-resistant acute Graft-versus-Host-Disease (SR-aGvHD), the most deadly complication in […]
Synthetic Biologics, Inc. (NYSE American: SYN) (“Synthetic Biologics” or the “Company”), a late-stage clinical company focused on developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, announced today the […]
In a new study, researchers at the University of Maryland School of Medicine (UMSOM) have found that the gut microbiome appears to play a key role in how well the body accepts a transplanted heart. […]
Valbiotis, a French Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, confirms its international expansion with the appointment of Murielle Cazaubiel, founder and former Executive Director of Biofortis Mérieux […]